Medtronic touts cost, treatment data on CRT devices
Medtronic (NYSE:MDT) today touted data showing that a pair of algorithms improved treatment and lowered costs for patients treated with its cardiac resynchronization therapy devices.
The Fridley, Minn.-based medical device giant said its AdaptivCRT and EffectiveCRT algorithms lowered costs and improved therapy delivery in heart failure patients with atrial fibrillation. Results from 1 of 3 analyses presented at the European Heart Rhythm Assn. Europace Cardiostim conference in Vienna this week showed that the AdaptivCRT program cut the lifetime cost of treatment by an average of €1,055 (about $1,174) in 3 European countries:
With AdaptivCRT
Without AdaptivCRT
Difference
Italy
€28,113.00
€29,215.16
€1,102.16
Spain
€29,618.89
€30,833.93
€1,215.04
U.K.
€29,425.37
€30,273.19
€847.82
The study also showed that the algorithm extends life expectancy by an average of 4 months, Medtronic said.
A 2nd study used data from the CRTee study to show that the EffectivCRT program improved left ventricular pacing by 19% compared to devices without the technology. A 3rd analysis of Medtronic’s CRT-defibrillators showed “a highly significant increase” in projected device longevity of up to 9 years for the Claria and Amplia devices and 8.1 years for the Viva XT CRT-Ds.
“These analyses reinforce Medtronic’s leadership in providing treatments and solutions that not only improve patient outcomes and CRT delivery, but also dramaticall...
Source: Mass Device - Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Clinical Trials Cardiac Rhythm Management Medtronic Source Type: news
More News: Atrial Fibrillation | Cardiac Resynchronization Therapy | Cardiology | Cardiovascular | Clinical Trials | Conferences | Heart | Heart Failure | Hospitals | Medical Devices | Study